Sun Pharma Signs Exclusive Deal with LIB Therapeutics for Lerodalcibep, Expanding Access to US$ 3.7 Billion PCSK9 Market
Cite this
Citations are auto-generated; verify before publishing. The analysis classification is PolicyDhara's, not the source's.
Research or analytical publication — an evidence-based assessment informing policy design and evaluation. Shapes the intellectual framework within which policy debates occur.
Summary
Sun Pharma has entered an exclusive agreement with LIB Therapeutics to commercialise Lerodalcibep across markets outside the US and China, gaining access to a US$ 3.7 billion PCSK9 market.
Key Facts
TypeAnalysis
SourceIndia Brand Equity Foundation
PublishedTuesday, 29 September 2026
Affected Population1.4 billion citizens, 5 million healthcare workers
Key Numbers
Health budget: Rs 90,958 crore (2025-26)
Target: 2.5% of GDP public health spending
1.5 lakh Health & Wellness Centres planned
Key Authorities
Key Stakeholders
Government Context
NDA IIIBJP-led NDA
LeftCentreRight